<DOC>
	<DOCNO>NCT00507091</DOCNO>
	<brief_summary>A Phase I open label study asses safety tolerability ZD6474 combination Irinotecan , 5-Fluorouracil Leucovorin ( FOLFIRI ) first second line therapy patient metastatic colorectal adenocarcinoma .</brief_summary>
	<brief_title>Phase I Irinotecan , 5-Fluorouracil Leucovorin Combination</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Confirmed metastatic colorectal adenocarcinoma 2 . Not amenable surgery radiation therapy 3 . Eligible first second line chemotherapy 1 . Brain metastasis spinal compression 2 . Last prior chemotherapy discontinue within 4 week start 3 . Last dose radiotherapy within 4 week start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>5-Fluorouracil</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>colorectal</keyword>
</DOC>